Johnson & Johnson (JNJ) vs Abbott Laboratories (ABT)
JNJ pairs stronger profitability and momentum with richer multiples; ABT is cheaper but has lagged
Qanvo's scorecard ranks ABT cheapest on valuation (100 versus 0) and JNJ ahead on profitability and quality (100 versus 0), earnings momentum (67 versus 33), technical momentum (100 versus 0), financial resilience (80 versus 20) and lower risk (75 versus 25). Growth is mixed with no clear leader, at 50 each: ABT has faster latest-year revenue growth of 10.00% versus 7.80%, while JNJ has the stronger three-year revenue compound rate of 5.60% versus 0.51%. Forward P/E, an analyst-estimate measure, is 17.80× for ABT and 24.15× for JNJ, and both trailing P/Es sit near five-year highs. Price returns over one year were 39.6% for JNJ and -19.5% for ABT. The central trade-off is a premium multiple with stronger fundamentals at JNJ against a lower multiple with weaker margins and a steep decline at ABT. Different business models (drug maker versus medical devices) limit how directly some ratios compare.
Business overview
Johnson & Johnson is a holding company in healthcare research, development, manufacture and sale, operating through Innovative Medicine and MedTech segments. Abbott Laboratories also discovers, develops, makes and sells healthcare products, but through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. The profile description for Abbott is cut off, so its segment detail is incomplete. By size, J&J is the larger company with a market cap of $682.13B (Mega tier) against $181.61B for Abbott (Large tier). Both are in the Healthcare sector, but J&J is classed as Drug Manufacturers - General while Abbott is Medical - Devices, so the business models differ. J&J's fiscal 2025 revenue was 64.12% Innovative Medicine and 35.88% MedTech; Abbott's was 48.27% Medical Devices, 20.17% Diagnostic Products, 19.07% Nutritional Products and 12.49% Established Pharmaceutical Products. Geographically, J&J drew 57.07% of fiscal 2025 revenue from the United States, against 39.84% for Abbott, which reports 37.17% as Non-US. Abbott's remaining geographic labels are abbreviated and not interpretable here.
- J&J's market cap of $682.13B is roughly four times Abbott's $181.61B.
- Medical Devices is 48.27% of Abbott's revenue, while MedTech is 35.88% of J&J's.
- The United States is 57.07% of J&J's revenue versus 39.84% of Abbott's.
Valuation
Abbott is the cheaper company on Qanvo's valuation scorecard (score 100 against 0 for J&J, a relative rank only). Trailing P/E is 38.63× for Abbott and 42.38× for J&J. Forward P/E, based on analyst estimates, is 17.80× for Abbott and 24.15× for J&J. Price/sales is 3.77× against 6.87×, EV/EBITDA 18.83× against 26.46×, and PEG 2.38× against 5.60×. Free-cash-flow yield is 3.72% for Abbott and 3.02% for J&J. Against their own five-year histories, J&J's trailing P/E of 42.38× sits just above its five-year maximum of 42.25× (median 23.63×, low 9.63×). Abbott's 38.63× is close to its maximum of 38.88× (median 30.77×, low 13.70×). Both are at the top of their ranges, though J&J is further above its median. Against healthcare peers, J&J's trailing P/E is at the 71st percentile (sector median 30.02×) and Abbott's at the 68th. On forward P/E, J&J is at the 71st percentile and Abbott at the 48th (sector median 18.34×). J&J's forward P/E is 55.42% above its industry median of 15.54×, while Abbott's is 5.93% below its industry median of 18.93×. J&J's higher multiples coincide with stronger profitability and a calmer risk profile in the scorecard, which may explain part of the premium. Abbott's discount coincides with weaker margins and a steep 1-year price decline, so cheaper does not mean better.
- Forward P/E is 17.80× for Abbott versus 24.15× for J&J, both analyst-estimate based.
- J&J's PEG of 5.60× is more than double Abbott's 2.38×.
- Free-cash-flow yield is 3.72% for Abbott against 3.02% for J&J.
- Both trailing P/Es sit near their five-year highs: 42.38× for J&J and 38.63× for Abbott.
Growth
The scorecard shows no clear growth leader (50 each). Reported revenue growth over the last year is 10.00% for Abbott and 7.80% for J&J; for the latest quarter it is 14.46% against 5.86%. Over three years, J&J's revenue compound rate is 5.60% against 0.51% for Abbott. Abbott has had three quarters of revenue acceleration, J&J none. Reported EPS fell for both: EPS growth over the last year is -66.16% for Abbott and -36.33% for J&J, and in the latest quarter -43.62% against -95.95%. J&J's quarterly net income of $210.0M in Q3 FY2026 compares with $5.53B in Q2. J&J's three-year EPS compound rate is 17.90%, versus -1.65% for Abbott. Annual EPS for both has been uneven, with large swings tied to fiscal 2023 and 2024. Annual revenue history: J&J rose from $79.99B in fiscal 2022 to $94.19B in 2025, steadily each year since 2021. Abbott went from $43.65B to $44.33B over the same span, with a dip in 2023. Analyst estimates, not reported results, point to next-fiscal-year EPS growth of 7.47% for Abbott and 4.31% for J&J. Consensus EPS for the current fiscal year is 11.11 for J&J and 5.52 for Abbott.
- Latest-quarter revenue growth is 14.46% for Abbott versus 5.86% for J&J.
- J&J's three-year revenue compound rate of 5.60% compares with 0.51% for Abbott.
- Latest-year EPS growth is -36.33% for J&J and -66.16% for Abbott.
- Analysts expect next-year EPS growth of 7.47% for Abbott and 4.31% for J&J (estimates).
Profitability, cash flow & financial health
JNJ leads on profitability and quality in Qanvo's scorecard (100 versus 0 for ABT, a relative rank within this pair). Its gross margin is 67.56% against 57.04% for ABT, and its operating margin is 25.17% against 15.00%. Net margin is 16.20% versus 9.75%. Returns on capital show the same gap: ROIC of 18.13% against 7.34%, and ROE of 20.02% against 9.22%. On cash flow, JNJ's trailing free cash flow is 20.59B with a 20.73% margin, while ABT's is 6.76B with a 14.01% margin. JNJ's free cash flow grew 7.93% year over year; ABT's fell 2.31%. Trends in margins are mixed: JNJ's operating margin slipped 0.92% over one year and ABT's fell 2.76%, though ABT's gross margin rose 3.05% while JNJ's fell 0.52%. ABT's revenue growth of 10.00% has not yet turned into better operating economics. On the balance sheet, JNJ's net debt/EBITDA is 1.02× against 2.43× for ABT, and interest coverage is 25.41× versus 7.67×. JNJ's current ratio is 1.02× versus 1.45× for ABT, so ABT has the stronger short-term liquidity. Debt/equity is 0.55× for JNJ and 0.61× for ABT.
- JNJ's operating margin of 25.17% compares with 15.00% for ABT.
- JNJ's ROIC of 18.13% is more than double ABT's 7.34%.
- JNJ's net debt/EBITDA of 1.02× is below ABT's 2.43×, and its interest coverage of 25.41× exceeds ABT's 7.67×.
- ABT has the higher current ratio at 1.45× versus 1.02× for JNJ.
Shareholder returns & capital allocation
ABT offers the higher dividend yield at 2.41% against 1.89% for JNJ, but it also pays out more of its earnings: a payout ratio of 93.33% versus 80.05%. A higher payout leaves less room for reinvestment or for absorbing an earnings dip. ABT's dividend per share over the last twelve months is 2.52 and JNJ's is 5.28; these are not comparable across different share prices. On dividend growth, ABT's three-year rate is 7.87% against 4.92% for JNJ. JNJ has the longer record, with 29 years of dividend growth versus 12 for ABT. JNJ's next ex-dividend date is Nov 24, 2026, with a quarterly payment of 1.34. On share count, ABT's shares changed by -0.63% over one year, a modest net reduction, while JNJ's rose 0.82%, a small net increase. In the latest fiscal year, JNJ spent 5.95B on buybacks and paid 12.38B in dividends, while ABT spent 893.0M on buybacks and paid 4.12B in dividends. Both companies direct most of their cash to dividends, with JNJ also running much larger repurchases in absolute terms.
- ABT's dividend yield of 2.41% is above JNJ's 1.89%.
- ABT's payout ratio of 93.33% is higher than JNJ's 80.05%, leaving less cushion.
- ABT's three-year dividend growth of 7.87% exceeds JNJ's 4.92%, though JNJ has 29 years of growth against 12.
- ABT's share count fell 0.63% over one year while JNJ's rose 0.82%.
Earnings intelligence
Over the last four reported quarters, JNJ's EPS surprises were 2.78% (Oct 13, 2026), 1.75%, 0.75% and 0.00%, with revenue surprises of 0.06%, 0.99%, 1.89% and 1.72%. ABT's EPS surprises were 0.00% (Oct 21, 2026), 2.34%, 0.88% and 0.00%, with revenue surprises of 0.18%, 0.59%, 1.49% and -2.89%. JNJ has an EPS beat streak of 3 against 0 for ABT, and Qanvo's scorecard ranks JNJ ahead on earnings momentum (67 versus 33). The stock reactions differ. JNJ moved -3.72%, -1.53%, 0.30% and 0.13% after those reports. ABT moved 0.06%, 12.78%, -4.68% and -11.02%. ABT's average earnings move over 8 quarters is 6.02% versus 1.52% for JNJ, so ABT's reports have carried larger price swings. Estimate revisions over 30 days are -0.41% for JNJ EPS and 0.06% for ABT EPS, a small edge to ABT on that single measure. Revenue revisions are -0.00% for JNJ and -0.64% for ABT. The next reports are Jan 26, 2027 for JNJ and Jan 28, 2027 for ABT; neither date is confirmed. No guidance figures are in the facts. JNJ's latest report was a modest beat but drew a negative reaction, while ABT's matched consensus with a flat reaction.
- JNJ's EPS beat streak is 3 versus 0 for ABT.
- ABT's 8-quarter average earnings move is 6.02% versus 1.52% for JNJ.
- The 30-day EPS revision is -0.41% for JNJ versus 0.06% for ABT, and the 30-day revenue revision is -0.64% for ABT versus -0.00% for JNJ.
- Neither next report date is confirmed: Jan 26, 2027 for JNJ and Jan 28, 2027 for ABT.
Technicals, relative performance & risk
JNJ leads on price return in every period in the ranking: 1 month 9.8% versus 0.6%, 3 months 6.2% versus -5.1%, 6 months 21.7% versus 19.1%, 1 year 39.6% versus -19.5%, 3 years 85.9% versus 3.5% and 5 years 70.7% versus -18.6%. With dividends reinvested, 1-year returns are 42.8% for JNJ and -18.0% for ABT. JNJ's relative strength rating is 90 against 48 for ABT. JNJ trades 1.73% above its 20-day average, 4.30% above its 50-day and 11.35% above its 200-day, and sits 3.98% below its 52-week high with an RSI of 56.43. ABT is 2.36% below its 20-day average, 0.80% above its 50-day and 3.14% above its 200-day, with an RSI of 45.51, and is 20.69% below its 52-week high. On risk, 30-day historical volatility is 29.90% for JNJ and 29.74% for ABT, nearly level. Beta is -0.05 versus 0.08, and 1-year maximum drawdown is -10.96% versus -36.51%. The scorecard ranks JNJ ahead on momentum and lower risk. Technicals conflict with valuation: JNJ's strength coincides with a forward P/E of 24.15 versus 17.80 for ABT, whom the scorecard ranks cheaper. This is descriptive, not a forecast.
- JNJ's 1-year price return is 39.6% versus -19.5% for ABT.
- JNJ is 11.35% above its 200-day average versus 3.14% for ABT.
- The 1-year maximum drawdown is -10.96% for JNJ versus -36.51% for ABT.
- The relative strength rating is 90 for JNJ versus 48 for ABT, while forward P/E is 24.15 versus 17.80.
Analyst & ownership sentiment
Analysts' opinions lean positive on both, though the ratings differ. ABT's rating score is 2 with a label of "Strong Buy" from 17 analysts, while JNJ's is 2.14 with a label of "Buy" from 11 analysts. The consensus breakdown shows 33 Buy and 10 Hold with no Sell for ABT, against 21 Buy, 16 Hold and 3 Sell for JNJ. Mean price targets are opinions: ABT's $121.00 implies 15.56% upside from $104.71, while JNJ's $287.45 implies 3.14% from $278.70. Over the last 30 days JNJ's EPS estimates moved -0.41% with one downgrade (Johnson Rice, Buy to Hold), while ABT's moved 0.06% with no rating changes. Institutions hold 82.30% of ABT and 74.50% of JNJ, with three-month changes of 3.50% and 1.38%; these filings lag by weeks. Insiders made no purchases at either in 90 days. ABT recorded 4 sales worth a net -$46.6M, JNJ 2 sales worth -$9.9M. Short interest is 1.10% of float at ABT (up 9.61%) and 0.70% at JNJ (up 1.80%), both low.
- ABT's mean target implies 15.56% upside versus 3.14% for JNJ, which is an analyst opinion, not a forecast.
- JNJ has 3 Sell ratings and ABT has none, out of 40 and 43 ratings respectively.
- Net insider selling over 90 days was -$46.6M at ABT versus -$9.9M at JNJ, with no insider buying at either.
- Short interest is 1.10% of float at ABT versus 0.70% at JNJ.
Risks & catalysts
Valuation is the main risk for JNJ: its trailing P/E is 42.38×, at the top of its five-year range (median 23.63×), and its forward P/E of 24.15× is 55.42% above the industry median of 15.54×. Its price is 3.98% below its all-time high after a 42.24% one-year gain, so a reversal would start from a stretched level. Recent news also mentions a law firm investigation and a mesothelioma damages ruling, though the facts give no detail on outcomes. Its EPS growth over the last year was -36.33%. ABT's risks are different: operating margin is 15.00% (down 2.76% over a year), net debt to EBITDA is 2.43× versus 1.02× at JNJ, and the one-year drawdown reached -36.51%. Its earnings reactions are large, averaging 6.02% over eight quarters, including 12.78% and -11.02% moves. Its trailing P/E is 38.63×, though forward P/E is 17.80×, which relies on analysts' estimates. Catalysts: ABT reports on Jan 28, 2027 and JNJ on Jan 26, 2027, both unconfirmed. JNJ's next ex-dividend date is Nov 24, 2026.
- JNJ's forward P/E of 24.15× compares with 17.80× for ABT, which makes JNJ more dependent on estimates being met.
- ABT's one-year maximum drawdown of -36.51% compares with -10.96% for JNJ.
- ABT's net debt to EBITDA of 2.43× is above JNJ's 1.02×, and its interest coverage is 7.67× versus 25.41×.
- Next earnings are Jan 26, 2027 for JNJ and Jan 28, 2027 for ABT, and JNJ goes ex-dividend on Nov 24, 2026.
Analysis written November 18, 2026. AI-generated, for information only; not investment advice.